CanSense Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $1.81M

  • Investors
  • 13

CanSense General Information

Description

Developer of non-invasive blood test technology designed for the early detection of bowel cancer. The company's solution enables primary care providers to screen for colorectal cancer without invasive procedures, enabling healthcare professionals to reduce mortality rates and minimize unnecessary colonoscopies.

Contact Information

Website
www.cansenseltd.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 408
  • Institute of Life Science 2, Swansea University
  • Swansea SA2 8PP
  • Wales, United Kingdom
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Vertical(s)
Digital Health, HealthTech, Life Sciences, Oncology
Corporate Office
  • Room 408
  • Institute of Life Science 2, Swansea University
  • Swansea SA2 8PP
  • Wales, United Kingdom

CanSense Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CanSense Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Later Stage VC $1.81M Completed Startup
12. Accelerator/Incubator Completed Startup
11. Accelerator/Incubator 18-Sep-2025 Completed Startup
10. Seed Round 22-Jul-2025 Completed Startup
9. Grant 01-May-2025 Completed Startup
8. Accelerator/Incubator 01-Jan-2025 Completed Startup
7. Accelerator/Incubator 05-Dec-2024 Completed Startup
6. Seed Round 08-Mar-2023 Completed Startup
5. Seed Round 01-Jan-2022 Completed Startup
4. Grant 01-Jan-2022 $1.6M Completed Startup
To view CanSense’s complete valuation and funding history, request access »

CanSense Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
To view CanSense’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

CanSense Patents

  • 8

    Total Documents Applications and Grants

  • Total Patents Families

  • 8

    Granted

  • Pending

  • Expiring in next 12 mo

CanSense Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018234280-A1 Method and apparatus for use in diagnosis and monitoring of colorectal cancer Active 15-Mar-2017
AU-2018234280-B2 Method and apparatus for use in diagnosis and monitoring of colorectal cancer Active 15-Mar-2017
EP-3596468-A1 Method and apparatus for use in diagnosis and monitoring of colorectal cancer Active 15-Mar-2017
EP-3596468-B1 Method and apparatus for use in diagnosis and monitoring of colorectal cancer Active 15-Mar-2017
EP-3596468-C0 Method and apparatus for use in diagnosis and monitoring of colorectal cancer Active 15-Mar-2017 G01N33/57535
To view CanSense’s complete patent history, request access »

CanSense Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CanSense Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
The Bayes Centre for Entrepreneurship Accelerator/Incubator
Life Science Hub Wales Corporation Minority
The Academy of Medical Sciences Corporation Minority
Barclays Eagle Lab Accelerator/Incubator
Plexal Accelerator/Incubator Minority
You’re viewing 5 of 13 investors. Get the full list »

Ready to get started?

Request a free trial

CanSense FAQs

  • When was CanSense founded?

    CanSense was founded in 2018.

  • Where is CanSense headquartered?

    CanSense is headquartered in Swansea, United Kingdom.

  • What is the size of CanSense?

    CanSense has 14 total employees.

  • What industry is CanSense in?

    CanSense’s primary industry is Diagnostic Equipment.

  • Is CanSense a private or public company?

    CanSense is a Private company.

  • What is the current valuation of CanSense?

    The current valuation of CanSense is .

  • What is CanSense’s current revenue?

    The current revenue for CanSense is .

  • How much funding has CanSense raised over time?

    CanSense has raised $3.61M.

  • Who are CanSense’s investors?

    The Bayes Centre for Entrepreneurship, Life Science Hub Wales, The Academy of Medical Sciences, Barclays Eagle Lab, and Plexal are 5 of 13 investors who have invested in CanSense.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process